Unmet Clinical Need

---

Cardiogenic Shock (CS) is a medical emergency with a mortality rate of 50-60%.¹ Patients with CS experience a series of disturbances in blood flow, pressure, and resistance that lead to the need for circulatory support. For heart failure patients who survive the initial CS crash and are salvaged, the key question becomes what comes next.

Today, Impella 5.5 is often used for post-salvage stabilization. While Impella 5.5 may be effective for initial stabilization, its mechanical bearings, purge system, external hardware, and ICU-dependent monitoring keep patients ICU-bound and non-dischargeable. 

The current gold standard may work for some CS Acute Myocardial Infarction (AMI) cases, where support needs may resolve within weeks. However, it is a poor fit for many CS-HF patients who want to get out of the hospital and back to life and are facing more long-term support needs. For these patients, Hemoglide has been designed to be the answer.

This figure from the Society for Cardiovascular Angioplasty & Intervention (SCAI) shows that in-hospital mortality and long-term mortality rates of CS are both very high.² We expect the Hemoglide VAD to provide both survival and quality of life benefits to patients who are primarily in shock stages C and D.